UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer |
|
|
Registrant’s telephone number, including area code (
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On December 31, 2020, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing the efficacy and safety results from the Company’s MOVEMENT trial of AXS-07 in the acute treatment of migraine (the “MOVEMENT Press Release”). The full text of the MOVEMENT press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
Additionally, on December 31, 2020, the Company issued a press release announcing the initiation of the Company’s ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) Phase 3 trial of AXS-05 (dextromethorphan- bupropion modulated delivery tablet) in Alzheimer’s disease agitation (the “ACCORD Press Release”). The full text of the ACCORD press release is filed as Exhibit 99.2 hereto, and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
99.1 |
| |
99.2 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Axsome Therapeutics, Inc. | |||
Dated: December 31, 2020 | By: | /s/ Herriot Tabuteau, M.D. | |
Name: | Herriot Tabuteau, M.D. | ||
Title: | President and Chief Executive Officer |
2